The latest episode of the Modern Lifescience podcast features a thought-provoking conversation with Nicholas Nadeau, the founder of Nadeau Innovation. The podcast, hosted by Jeremy Derosier, provides a platform for experts in the field to delve into critical issues surrounding the impact of technological advancements on the industry. In this episode, the discussion centers around the transformative influence of artificial intelligence (AI) and robotics on the medical device industry.
Nadeau Innovation, under the leadership of Nicholas Nadeau, aims to offer expert guidance and strategic direction to hard tech startups and corporate innovations, fostering growth and technological advancement. With a diverse background in mechanical and biomedical engineering, Nicholas brings a unique perspective to the table as he discusses the future of medtech, a field he is deeply passionate about.
The conversation kicks off with Nicholas sharing his intriguing journey into the world of AI and robotics. His initial aspirations were geared towards a career in orthopedic surgery. However, his path took an unexpected turn, leading him into mechanical engineering, and subsequently, into biomedical engineering. This shift proved to be a game-changer, ushering him into the medtech field. Nicholas recounts his time at an R&D company named Rogue Research, where he worked on a diverse range of moonshot projects. From developing surgical robots to creating cognitive neuroscience imaging and stimulation devices, his experiences at Rogue Research equipped him with a holistic understanding of the industry.
Following his stint at Rogue Research, Nicholas dived into the vibrant startup scene in Montreal. Here, he worked with Aon3D, a 3D printing startup. The company’s mission was to develop high-performance, open material, 3D printing systems aimed at the biomedical, defense, and aerospace market. At Aon3D, Nicholas delved into the potential of 3D printing for creating personalized implants. By using only the necessary material, he could create implants that were more efficient and patient-specific, ushering in a new era of personalized medicine.
The podcast episode then seamlessly transitions into a discussion on the overarching effects of AI on the medical device market. Nicholas acknowledges the slow pace of change in the heavily regulated medical market but remains optimistic about the transformative power of AI. He provides examples of how AI can be used to streamline and improve various aspects of the medical field. For instance, he discusses the potential use of AI to map the patient journey through pelvic organ prolapse, aiding in determining the optimal next steps for treatment.
A major highlight of the episode is Nicholas’s insights into the challenges faced by companies when deploying AI. He underscores the pivotal role of stakeholder alignment in the success of AI projects. He observes that mismatches in expectations among different stakeholders often lead to project derailment. Nicholas emphasizes that at its core, AI is a design problem and a user experience problem. The tools used are merely a means to an end. The real focus should be on the users and their needs. Keeping users at the heart of AI projects ensures their success and maximizes their impact.
Towards the end of the episode, Nicholas delves into the “4Ds” that AI and robotics can address: dull, dangerous, dirty, and dear tasks. He posits that any intelligent system application that doesn’t fit into at least one of these categories is likely not providing real-world value. Whether it’s automating dull and dirty tasks like UV sanitizing or leveraging AI systems to improve patient outcomes, the potential applications of AI and robotics are as vast as they are impactful.
In conclusion, this episode of the Modern Lifescience podcast offers a wealth of insights into the intersection of AI, robotics, and medtech. Nicholas’s expertise, coupled with his innovative approach and commitment to enhancing patient outcomes through technology, make this a must-listen for industry professionals, tech enthusiasts, and anyone interested in the future of the medtech industry.
All rights reserved. Modern LifeScience